Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17172975 | 0.81 | MEN1 (0.35) | MEN1KMT2ATACR1RIPK1DPP4 | |
| SCHEMBL18702092 | 0.80 | DPP4 (0.43) | MEN1KMT2AALDH1A1HTTRIPK1 | |
| SCHEMBL14217176 | 0.78 | MEN1 (0.33) | MEN1KMT2ATACR1RIPK1DPP4 | |
| SCHEMBL9976646 | 0.76 | GLRA1 (0.37) | MEN1KMT2ATACR1ALDH1A1HTT | |
| SCHEMBL19885262 | 0.75 | TACR1 (0.36) | MEN1KMT2ATACR1 | |
| SCHEMBL10190233 | 0.75 | NR1H2 (0.50) | MEN1KMT2AALDH1A1DPP4 | |
| SCHEMBL10223225 | 0.73 | RIPK1 (0.34) | MEN1KMT2ATACR1RIPK1 | |
| SCHEMBL321299 | 0.73 | RIPK1 (0.35) | RIPK1 | |
| SCHEMBL10223178 | 0.73 | RIPK1 (0.34) | MEN1KMT2ATACR1RIPK1 | |
| SCHEMBL1972135 | 0.73 | RIPK1 (0.34) | MEN1KMT2ATACR1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153831-A1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | CYP4B1, CYP1B1, AADAC | MEN1 692/4885KMT2A 1607/4885TACR1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.